About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT04271397

Immunological Biomarkers in Tuberculosis Management

Tuberculosis (TB) is the leading cause of death by infectious disease in the world, responsible for 1.6 million deaths in 2017. The treatment of active TB requires at least a 6-month combined antibiot...

Lead sponsor: Hospices Civils de Lyon•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Florence ADER, M.D., Ph.D

CONTACT

04 72 07 11 07 florence.ader@chu-lyon.fr

Oana DUMITRESCU, M.D., PhD

CONTACT

04 72 07 11 07 oana.dumitrescu@chu-lyon.fr

Sponsors

Lead Sponsor

Hospices Civils de Lyon

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult ≥ 18 year-old
•Patients having given written consent
•Patients accepting a follow up ≥ 6 months
•Proven active tuberculosis (positive direct examination and/or PCR)
•Latent tuberculosis infection assessed by positive IGRA

Exclusion Criteria

•Malignant solid tumor
•Malignant hemopathy
•Solid organ transplantation or hematopoietic stem cell transplantation
•Immunosuppressive treatments (i.e. biologics, calcineurin inhibitors, corticosteroids)
•Auto-inflammatory disease
•Chronic liver diseases
•Chronic infection with HIV, HCV (hepatitis C virus) or HBV (hepatitis B virus)
•Antimycobacterial treatment initiated \> 7 days
•Pregnancy or breastfeeding
•Refusal to participate to the study
•Persons deprived of their liberty by judicial or administrative decision
•Protected adults
•Patients not affiliated to health-care social security
•The homeless

Related studies

RECRUITINGPhase 2

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

NCT06192160 · Pulmonary Tuberculosis

RECRUITINGPhase 2

Evaluating the Safety and Immunogenicity of MTBVAC

NCT05947890 · HIV I Infection, Tuberculosis

Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)

NCT05989802 · Tuberculosis, Diagnostics, and more

Assessing Diagnostics At Point-of-care for Tuberculosis

NCT05941052 · Tuberculosis

RECRUITINGPhase 2

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

NCT06272812 · Tuberculosis (TB)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 12, 2024Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment60

Start dateSep 2019

Last updatedAug 12, 2024

Condition

Tuberculosis Tuberculosis Infection

Locations shown

Service des Maladies Infectieuses - Hôpital de la Croix Rousse - Hospices Civils de Lyon

Lyon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions